This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: 111/22/2981    most recent CIRCULATIONAHA.104.504340v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schmidt-Lucke, C. Articles by Zeiher, A. M. Search for Related Content PubMed PubMed Citation Articles by Schmidt-Lucke, C. Articles by Zeiher, A. M. Related Collections Pathophysiology Related Article

(Circulation. 2005;111:2981-2987.)
© 2005 American Heart Association, Inc.

Vascular Medicine

Reduced Number of Circulating Endothelial Progenitor Cells Predicts Future Cardiovascular Events

Proof of Concept for the Clinical Importance of Endogenous Vascular Repair

Caroline Schmidt-Lucke, MD^*; Lothar Rössig, MD^*; Stephan Fichtlscherer, MD; Mariuca Vasa, MD; Martina Britten, MD; Ulrike Kämper, BSc; Stefanie Dimmeler, PhD; Andreas M. Zeiher, MD

From Molecular Cardiology, Department of Medicine III, J.W. Goethe University, Frankfurt, Germany.

Correspondence to Stefanie Dimmeler, PhD, or Andreas M. Zeiher, MD, Department of Internal Medicine III, Division of Cardiology, J.W. Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany. E-mail dimmeler{at}em.uni-frankfurt.de or zeiher@em.uni-frankfurt.de

Received September 7, 2004; revision received December 20, 2004; accepted December 21, 2004.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— The maintenance of endothelial integrity plays a critical role in preventing atherosclerotic disease progression. Endothelial progenitor cells (EPCs) were experimentally shown to incorporate into sites of neovascularization and home to sites of endothelial denudation. Circulating EPCs may thus provide an endogenous repair mechanism to counteract ongoing risk factor–induced endothelial injury and to replace dysfunctional endothelium.

Methods and Results— In 120 individuals (43 control subjects, 44 patients with stable coronary artery disease, and 33 patients with acute coronary syndromes), circulating EPCs were defined by the surface markers CD34⁺KDR⁺ and analyzed by flow cytometry. Cardiovascular events (cardiovascular death, unstable angina, myocardial infarction, PTCA, CABG, or ischemic stroke) served as outcome variables over a median follow-up period of 10 months. Patients suffering from cardiovascular events had significantly lower numbers of EPCs (P<0.05). Reduced numbers of EPCs were associated with a significantly higher incidence of cardiovascular events by Kaplan-Meier analysis (P=0.0009). By multivariate analysis, reduced EPC levels were a significant, independent predictor of poor prognosis, even after adjustment for traditional cardiovascular risk factors and disease activity (hazard ratio, 3.9; P<0.05).

Conclusions— Reduced levels of circulating EPCs independently predict atherosclerotic disease progression, thus supporting an important role for endogenous vascular repair to modulate the clinical course of coronary artery disease.

Key Words: atherosclerosis • coronary disease • stem cells, endothelial • endothelium • prognosis

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
The integrity and functional activity of the endothelial monolayer play a critical role in atherogenesis. Cardiovascular risk factors induce endothelial injury and a cascade of proinflammatory events, resulting in infiltration of monocytic cells and smooth muscle cell proliferation, which lead to the formation of atherosclerotic lesions.¹ Ultimately, atherosclerotic plaque erosion and rupture cause myocardial infarction and sudden cardiovascular death.² Therefore, the maintenance of endothelial integrity is of crucial importance for preventing the triggering of these processes.

Recent studies have identified a population of presumably bone marrow–derived cells, called circulating endothelial progenitor cells (EPCs), that can be isolated from bone marrow or circulating, blood-derived, mononuclear cells^3–5; express a variety of endothelial surface markers⁶; incorporate into sites of neovascularization^7–9; and home to sites of endothelial denudation.^10–12 Initial clinical studies demonstrated that risk factors for atherosclerosis are associated with reduced levels of circulating EPCs¹³ and that the functional integrity of the endothelium correlates with the activities of EPCs.¹⁴ These observations prompted the hypothesis that circulating EPCs may provide an endogenous repair mechanism to counteract ongoing risk factor–induced endothelial cell injury and to replace dysfunctional endothelium.

Therefore, we investigated whether levels of circulating EPCs correlate with atherosclerotic disease progression to establish a clinically meaningful role of ongoing endogenous endothelial repair mediated by circulating EPCs.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Patients and Control Subjects
The study population comprised 120 of 340 subjects randomly recruited in a single center between October 2000 and June 2004. Forty-four patients had stable coronary artery disease (CAD), defined as angiographically documented CAD and the absence of acute coronary syndromes (ACS) for 3 months before blood samples were drawn. Thirty-three patients were studied with unstable CAD defined as de novo angina, crescendo angina, or angina at rest. Patients with ACS were further stratified for troponin T positivity to account for potential effects of myocardial necrosis on EPC levels. Extent of disease was quantified in all patients by the number of coronary arteries affected. Inclusion criteria were age from 18 to 85 years, signed written informed consent, documented CAD for patients with stable CAD or ACS (Braunwald IIIB) or acute myocardial infarction (both non–ST-segment and ST-segment myocardial infarction). Exclusion criteria were clinical or biochemical evidence for the presence of concomitant inflammatory disease, chronic renal insufficiency (serum creatinine 1.4 mmol/L), impaired left ventricular ejection fraction (<45%), autoimmune or malignant disease, thrombocytopenia (<100 000/L), anemia (hemoglobin <8.5 g/dL), inability to understand the consent form, participation in or consent to participate in another study, previous coronary bypass surgery, severe peripheral arterial occlusive disease, or atrial fibrillation. Forty-three healthy subjects without any evidence of CAD by history and physical examination served as a control group. All study participants gave written informed consent, and the study was approved by the ethics committee of J.W. Goethe University (Frankfurt, Germany).

Definition of Risk Factors for CAD
Hypertension was defined as a history of hypertension for >1 year requiring the initiation of antihypertensive therapy by the primary physician. Smoking was defined as a history of smoking >2 pack-years and/or smoking in the last year. Positive family history of CAD was defined as documented evidence of premature CAD in a close relative (men <55 and women <65 years of age).¹⁵ Diabetes mellitus was defined as the need for oral antidiabetic drug therapy or insulin use. We calculated a score giving the risk of an individual subject to develop cardiovascular disease by considering age >65 years, male sex, hypertension, diabetes, smoking, and positive family history of CAD as single cardiovascular risk factors.¹⁶

Flow Cytometry
Detection of EPCs was performed as previously described.¹³ In brief, 100 µL peripheral blood was immunostained with monoclonal antibodies against human CD34 (Becton Dickinson; PerCP conjugated) and against human KDR (Sigma), followed by an PE-conjugated secondary antibody. Isotype-identical antibodies served as controls (Becton Dickinson). After incubation, cells were lysed, washed with PBS, and fixed in 4% paraformaldehyde before analysis of 70 000 events after exclusion of debris and platelets.

To assess the reproducibility of EPC measurements, circulating EPCs were measured twice from the same subjects (n=22) from 2 separate blood samples, revealing a very close correlation (r=0.86, P<0.0001).

Long-Term Follow-Up
Clinical long-term follow-up was performed through a questionnaire sent to patients and telephone contact. All information about potential cardiovascular events was validated by source data, including analysis of coronary angiograms, discharge letters, or charts of hospital stays. Cardiovascular death was defined as death from myocardial infarction or documented sudden death. Unstable angina pectoris was defined as hospitalization for unstable angina pectoris of Braunwald IIB or IIIB. Myocardial infarction was defined as an elevation of creatine kinase serum levels >2 times the upper limit of normal or new ST elevation (>0.1 mV) in 2 leads. Progression of coronary atherosclerosis was defined as the need for coronary revascularization of de novo lesions (percutaneous coronary intervention or bypass surgery) because of documented ischemia.

Statistical Analysis
Data are expressed as mean±SD. Continuous variables were tested for normal distribution with the Kolmogorov-Smirnov test. Not normally distributed continuous variables (age, risk factor score, EPC numbers, extent of disease and high-sensitivity C-reactive protein [hs-CRP]) were compared by the Mann-Whitney U test. Comparisons between groups were analyzed by t test (2 sided) or ANOVA for normally distributed variables with >2 subgroups and by the Kruskal-Wallis test for nonnormally distributed variables. Post hoc range tests and pairwise multiple comparisons were performed with the t test (2 sided) with least-significant-difference adjustment. Comparison of categorical variables was generated by the Pearson ² test. Multivariate linear regression analysis and nonparametric bivariate correlation (Spearman’s rank correlation coefficient) were used to correlate circulating EPC counts with cardiovascular risk factors. To identify independent determinants of EPC numbers, a multivariate linear regression analysis for various cardiovascular risk factors was performed. Cumulative event-free survival was univariately evaluated by Kaplan-Meier analysis (log-rank test). Cox proportional-hazard ratio was used to estimate the relative risk for major adverse cardiac events and the association with identified variables. Hazard ratios (HR) and 95% CIs are given. We considered sensitivity and specificity for the identification of high-risk patients of equal importance. Therefore, in receiver-operating characteristic (ROC) curve analyses, the best prognosticator for event-free survival was considered to be the parameter that gave the highest product of sensitivity and specificity for predicting major adverse cardiac events. Statistical significance was assumed if a null hypothesis could be rejected at P0.05. All statistical analysis was performed with SPSS, version 11.5 (SPSS Inc).

	Results

Top Abstract Introduction Methods Results Discussion References

 
The baseline characteristics of the 120 subjects are summarized in Table 1. As expected, patients with documented CAD had a significantly higher number of risk factors, were slightly but significantly older, and more frequently were treated with statins, platelet inhibitors, and ACE inhibitors/AT-1 receptor blockers. Patients with ACS differed from patients with stable CAD with respect to the incidence of smoking, hs-CRP serum levels, and LDL serum cholesterol levels, which were all higher in patients with ACS. In addition, patients with ACS were less likely to be treated with statins before inclusion in the study.

View this table: [in this window] [in a new window]   TABLE 1. Patients’ Baseline Characteristics

Determinants of Circulating EPC Levels
Figure 1A shows that control subjects had significantly higher levels of EPCs compared with patients with documented CAD. By univariate analysis for the entire cohort, the classic risk factors of age, hypertension, smoking, and family history of CAD, as well as disease activity and extent of coronary atherosclerotic involvement, were inversely correlated with the number of circulating EPCs (Table 2). Figure 1B and 1C illustrates the inverse relation between age and EPC levels and the reduced EPC levels in subjects with a positive family history of premature CAD, respectively. By multivariate analysis, age and a positive family history of CAD remained the only significant independent predictors of a reduced number of EPCs (Table 3).

View larger version (26K): [in this window] [in a new window]   Figure 1. A, Percentage of circulating CD34+KDR+-EPC/PMNCs in control subjects and patients with stable CAD and troponin-negative (trop-neg) and troponin-positive (trop-pos) ACS. B, Correlation of CD34+KDR+-EPCs with age in healthy control subjects and patients with stable CAD. C, Reduced numbers of CD34+KDR+-EPCs in healthy control subjects and patients with stable CAD with positive family history of CAD.

View this table: [in this window] [in a new window]   TABLE 2. Univariate Correlation Between Disease Activity, Cardiovascular Risk Factors, and CD34+KDR+-EPCs in 120 Individuals

View this table: [in this window] [in a new window]   TABLE 3. Multivariate Analysis Between Disease Activity, Cardiovascular Risk Factors, and CD34+KDR+-EPCs

Although we did not detect a significant augmentation of EPCs in patients with ACS, which likely reflects the early blood sampling, we repeated both the univariate and multivariate analyses in the subcohort restricted to control subjects and stable CAD patients (n=87). As illustrated in Table I of the Data Supplement, when patients with ACS were excluded, identical results were obtained with age and family history as the only independent significant predictors for reduced EPC levels. Finally, even with the analysis restricted to the subgroup of healthy control subjects only (n=43), age and a positive family history of premature CAD independently predicted reduced EPC levels (Table II in the Data Supplement), confirming the strong influence of these risk factors on EPC levels.

Circulating EPC levels and Atherosclerotic Disease Progression
The median duration of follow-up was 10.0±12.1 months (range, 1 to 48 months). During follow-up, a total of 11 patients experienced a cardiovascular event (Table 4).

View this table: [in this window] [in a new window]   TABLE 4. Cardiovascular Events During Long-Term Follow-Up

Patients suffering from a cardiovascular event during follow-up had significantly lower EPC levels at inclusion in the study, with 0.0067±0.0097 per 100 peripheral mononuclear cells (PMNCs) compared with 0.02±0.02 per 100 PMNCs (P<0.05) in patients without a cardiovascular event.

When patients were categorized into quintiles according to EPC levels, those patients in the lowest quintile had a significantly (P<0.05) higher incidence of cardiovascular events during follow-up. To maximize the predictive power of EPC levels, we used ROC curve analysis over the entire dynamic range of EPC numbers to identify the threshold level for EPCs providing the highest predictive value for the occurrence of cardiovascular events during follow-up (Figure 2). Kaplan-Meier analysis revealed a significantly increased incidence of cardiovascular events in those patients with levels of circulating EPCs below the threshold (CD34⁺KDR⁺-EPC 0.0038) identified by ROC curve analysis for maximized predictive value (Figure 3). Table 5 illustrates that the crude HR, measured by the Cox proportional-hazard regression model, for suffering a cardiovascular event during follow-up was 6.3 (P=0.003). As expected, the presence of ACS had an impact on prognosis (univariate HR, 2.03; 95% CI, 1.2 to 3.5; P=0.006). However, even when adjusted for disease activity and overall risk factor load for CAD, low numbers of circulating EPCs were associated with a significantly, 4-fold, increased risk of suffering a cardiovascular event during follow-up (Table 5). Thus, the number of circulating EPCs independently predicts atherosclerotic disease progression.

View larger version (15K): [in this window] [in a new window]   Figure 2. ROC curve showing correlation between major adverse cardiac events and levels of circulating CD34+KDR+-EPCs. R2=0.769. R2=1.0 denotes perfect correlation; R2=0.5 denotes no correlation.

View larger version (16K): [in this window] [in a new window]   Figure 3. Event-free survival according to levels of circulating CD34+KDR+-EPCs defined by ROC curve analysis.

View this table: [in this window] [in a new window]   TABLE 5. Crude, Disease Activity–Adjusted, and Risk Factor-Adjusted Relative Risks of a First Major Cardiovascular Event in Patients With Low EPC Counts

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The results of the present study confirm and extend previous reports suggesting that the levels of circulating EPCs may be a surrogate marker of vascular function¹⁴ and cumulative cardiovascular risk.¹³ Most importantly, however, to the best of our knowledge, this is the first study to document that reduced levels of circulating EPCs independently predict atherosclerotic disease progression. Thus, our data provide clinical evidence for the hypothesis that circulating EPCs contribute to ongoing vascular repair.

Endothelial cell injury is regarded as the classic stimulus for the development of atherosclerotic lesions.¹⁷ Indeed, not only do classic risk factors for atherosclerosis induce endothelial injury, but impaired endothelial function predicts the risk of subsequent cardiovascular events.^18–21 Ultimately, endothelial damage represents a balance between the magnitude of injury and the capacity for repair. Recent experimental studies suggest that EPCs may contribute to ongoing endothelial repair by providing a circulating pool of cells that can home to denuded parts of the artery after balloon injury^10,11 or could replace dysfunctional endothelial cells.¹⁴

An impairment of this repair capacity may affect atherosclerotic disease progression. We have previously shown that classic risk factors for atherosclerosis are associated with reduced number and function of circulating EPCs.¹³ More recently, levels of circulating EPCs were shown to correlate with endothelial vasodilator function,¹⁴ cerebral infarction,²² and coronary collateral support in patients with CAD,²³ suggesting an important role of circulating EPCs in vascular homeostasis. The present study now documents that the level of circulating EPCs is an independent predictor of future cardiovascular events. Thus, taken together, these findings suggest that circulating EPCs are important for maintaining the functional integrity of the endothelial monolayer and exert important functions of vascular repair of continuous risk factor–induced endothelial injury.

The reduction in circulating EPC number may be secondary to a variety of mechanisms: exhaustion of the pool of progenitor cells in the bone marrow, reduced mobilization, or reduced survival and/or differentiation. The significant inverse correlation between patient age and levels of circulating EPCs reported previously^13,14,24 and in the present study may indicate that continuous endothelial damage will lead to an eventual depletion or exhaustion of a presumed finite supply of EPCs.²⁵ In analogy to the lympho-hematopoietic stem cell system in which basal hematopoiesis is maintained in aging but the capacity to react to stress-induced mobilization gradually declines with increased age,²⁶ atherosclerosis-prone apolipoprotein E^–/– mice exhibit significantly reduced vascular progenitor cells in the bone marrow with increased age.²⁷ Moreover, risk factors for atherosclerosis most likely directly influence the mobilization and survival of EPCs via impairing nitric oxide bioavailability. Indeed, mice deficient in endothelial nitric oxide synthase demonstrate a profound impairment in ischemia- or exercise-induced mobilization of EPCs.^28,29 In addition, EPCs derived from high-risk patients become senescent more rapidly,¹⁴ a process in part reversible by stimulating the Akt–nitric oxide synthase pathway.^30,31 Finally, risk factors may modulate the mechanisms that facilitate homing and differentiation of circulating EPCs.³² Thus, it is most likely that risk factors for atherosclerosis synergistically act on a variety of mechanisms that culminate in reduced levels of circulating EPCs. However, the lack of correlation between CRP and circulating EPC levels may indeed indicate that levels of circulating EPCs not only are a marker of an unspecific inflammation but also reflect endogenous vascular repair capacity in the presence of ongoing risk factor–induced endothelial injury. Clearly, the nature of our clinical study does not permit us to dissect the individual components leading to the impaired vascular repair capacity associated with reduced levels of EPCs. In addition, impaired functional activity of the EPCs may further amplify the reduced repair capacity. Indeed, in a subset of our patients, the number of CD34⁺KDR⁺-EPCs detected by fluorescence-activated cell sorter analysis correlated closely with the migratory capacity to vascular endothelial growth factor (r=0.47, P<0.01; n=31) and with an EPC culture assay (r=0.46, P<0.02; n=26). Thus, further studies should investigate whether functional properties of EPCs such as migratory capacity or colony forming capacity may provide additional prognostic information in addition to simply measuring the number of circulating EPCs. Likewise, assessing the number of the more immature circulating EPCs, as defined by the surface marker CD133,⁶ may provide additional mechanistic insights.

In summary, reduced levels of circulating EPCs independently predict future cardiovascular events, thus supporting an important role for endogenous vascular repair to modulate the clinical course of CAD. Importantly, statin³³ therapy and physical exercise,²⁹ both of which are known to exert beneficial effects in primary and secondary prevention of atherosclerosis, were recently shown to augment the number and function of EPCs. Thus, monitoring the levels of circulating EPCs as a surrogate biological marker might be specifically useful for identifying novel therapeutic approaches targeted to enhance endogenous vascular repair capacity and thereby modify the progression of cardiovascular disease.

	Acknowledgments

 
This study was supported by the Deutsche Forschungsgemeinschaft and SFB 553 (project C5 to Dr Zeiher) and Di 600/4-1 (Dr Dimmeler). Dr Rössig received a grant from the Heinrich and Fritz Riese Stiftung, Frankfurt, Germany. We are grateful to Rebeca Salguero Palacios and Marga Müller-Ardogan for expert assistance. We also thank all our volunteers and patients, especially the police choir of Frankfurt, Germany, for volunteering as healthy control subjects.

	Footnotes

 
*Drs Schmidt-Lucke and Rössig contributed equally to this article.

The online-only Data Supplement can be found with this article at http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.104.504340/DC1.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135–1143.[Abstract/Free Full Text]
   
2. Burke AP, Farb A, Malcom GT, Liang Y-H, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997; 336: 1276–1282.[Abstract/Free Full Text]
   
3. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner J. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275: 964–967.[Abstract/Free Full Text]
   
4. Shi Q, Rafii S, Wu M, Wijelath E, Yu C, Ishida A, Fujita Y, Kothari S, Mohle R, Sauvage L, Moore M, Storb R, Hammond W. Evidence for circulating bone marrow-derived endothelial cells. Blood. 1998; 92: 362–367.[Abstract/Free Full Text]
   
5. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 2000; 105: 71–77.[Medline] [Order article via Infotrieve]
   
6. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MAS, Rafii S. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood. 2000; 95: 952–958.[Abstract/Free Full Text]
   
7. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner J, Asahara T. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999; 5: 434–438.[CrossRef][Medline] [Order article via Infotrieve]
   
8. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003; 9: 653–660.[CrossRef][Medline] [Order article via Infotrieve]
   
9. Urbich C, Heeschen C, Aicher A, Dernbach E, Zeiher AM, Dimmeler S. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation. 2003; 108: 2511–2516.[Abstract/Free Full Text]
   
10. Walter D, Rittig K, Bahlmann F, Kirchmair R, Silver M, Murayama T, Nishimura H, Losordo D, Asahara T, Isner J. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow–derived endothelial progenitor cells. Circulation. 2002; 105: 3017–3024.[Abstract/Free Full Text]
    
11. Griese D, Ehsan A, Melo L, Kong D, Zhang L, Mann M, Pratt R, Mulligan R, Dzau V. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation. 2003; 108: 2710–2715.[Abstract/Free Full Text]
    
12. Fujiyama S, Amano K, Uehira K, Yoshida M, Nishiwaki Y, Nozawa Y, Jin D, Takai S, Miyazaki M, Egashira K, Imada T, Iwasaka T, Matsubara H. Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells. Circ Res. 2003; 10: 980–989.
    
13. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher A, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001; 89: e1–e7.[CrossRef][Medline] [Order article via Infotrieve]
    
14. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003; 348: 593–600.[Abstract/Free Full Text]
    
15. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D, for the European Society of Cardiology, American Heart Association, and American College of Cardiology. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis. 2004; 173: 381–391.[CrossRef][Medline] [Order article via Infotrieve]
    
16. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990; 81: 491–497.[Abstract/Free Full Text]
    
17. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340: 115–26.[Free Full Text]
    
18. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000; 101: 1899–1906.[Abstract/Free Full Text]
    
19. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000; 101: 948–954.[Abstract/Free Full Text]
    
20. Halcox JPJ, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KRA, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002; 106: 653–658.[Abstract/Free Full Text]
    
21. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation. 2002; 105: 1567–1572.[Abstract/Free Full Text]
    
22. Taguchi A, Matsuyama T, Moriwaki H, Hayashi T, Hayashida K, Nagatsuka K, Todo K, Mori K, Stern DM, Soma T, Naritomi H. Circulating CD34-positive cells provide an index of cerebrovascular function. Circulation. 2004; 109: 2972–2975.[Abstract/Free Full Text]
    
23. Lambiase PD, Edwards RJ, Anthopoulos P, Rahman S, Meng YG, Bucknall CA, Redwood SR, Pearson JD, Marber MS. Circulating humoral factors and endothelial progenitor cells in patients with differing coronary collateral support. Circulation. 2004; 109: 2986–2992.[Abstract/Free Full Text]
    
24. Scheubel RJ, Zorn H, Silber RE, Kuss O, Morawietz H, Holtz J, Simm A. Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol. 2003; 42: 2073–2080.[Abstract/Free Full Text]
    
25. Dimmeler S, Vasa-Nicotera M. Aging of progenitor cells: limitation for regenerative capacity? J Am Coll Cardiol. 2003; 42: 2081–2082.[Free Full Text]
    
26. Geiger H, Van Zant G. The aging of lympho-hematopoietic stem cells. Nat Immunol. 2002; 3: 329–333.[CrossRef][Medline] [Order article via Infotrieve]
    
27. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, Wang T, Gregg D, Ramaswami P, Pippen AM, Annex BH, Dong C, Taylor DA. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation. 2003; 108: 457–463.[Abstract/Free Full Text]
    
28. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, Zeiher AM, Dimmeler S. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med. 2003; 4: 1370–1376.
    
29. Laufs U, Werner N, Link A, Endres M, Wassmann S, Jurgens K, Miche E, Bohm M, Nickenig G. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation. 2004; 109: 220–226.[Abstract/Free Full Text]
    
30. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001; 108: 391–397.[CrossRef][Medline] [Order article via Infotrieve]
    
31. Assmus B, Urbich C, Aicher A, Hofmann WK, Haendeler J, Rossig L, Spyridopoulos I, Zeiher AM, Dimmeler S. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res. 2003; 92: 1049–1055.[Abstract/Free Full Text]
    
32. Dimmeler S, Zeiher AM. Vascular repair by circulating endothelial progenitor cells: the missing link in atherosclerosis? J Mol Med. 2004; 83: 671–677.
    
33. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher A, Dimmeler S. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001; 103: 2885–2890.[Abstract/Free Full Text]
    

Related Article:

Issue Highlights
Circulation 2005 111: 2865. [Full Text]

This article has been cited by other articles:

				D. R. Seals, C. A. DeSouza, A. J. Donato, and H. Tanaka Habitual exercise and arterial aging J Appl Physiol, October 1, 2008; 105(4): 1323 - 1332. [Abstract] [Full Text] [PDF]

				A. Surdacki, E. Marewicz, E. Wieteska, G. Szastak, T. Rakowski, E. Wieczorek-Surdacka, D. Dudek, J. Pryjma, and J. S. Dubiel Association between endothelial progenitor cell depletion in blood and mild-to-moderate renal insufficiency in stable angina Nephrol. Dial. Transplant., July 1, 2008; 23(7): 2265 - 2273. [Abstract] [Full Text] [PDF]

				R. P.W. Rouhl, R. J. van Oostenbrugge, J. Damoiseaux, J.-W. C. Tervaert, and J. Lodder Endothelial Progenitor Cell Research in Stroke: A Potential Shift in Pathophysiological and Therapeutical Concepts Stroke, July 1, 2008; 39(7): 2158 - 2165. [Abstract] [Full Text] [PDF]

				T. J. Povsic and P. J. Goldschmidt-Clermont Review: Endothelial progenitor cells: markers of vascular reparative capacity Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 199 - 213. [Abstract] [PDF]

				V. M. Miller and S. P. Duckles Vascular Actions of Estrogens: Functional Implications Pharmacol. Rev., June 1, 2008; 60(2): 210 - 241. [Abstract] [Full Text] [PDF]

				C Kalka and I. Baumgartner Gene and stem cell therapy in peripheral arterial occlusive disease Vascular Medicine, May 1, 2008; 13(2): 157 - 172. [Abstract] [PDF]

				G. P. Fadini, S. de Kreutzenberg, M. Albiero, A. Coracina, E. Pagnin, I. Baesso, A. Cignarella, C. Bolego, M. Plebani, G. B. Nardelli, et al. Gender Differences in Endothelial Progenitor Cells and Cardiovascular Risk Profile: The Role of Female Estrogens Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 997 - 1004. [Abstract] [Full Text] [PDF]

				K. Chu, K.-H. Jung, S.-T. Lee, H.-K. Park, D.-I. Sinn, J.-M. Kim, D.-H. Kim, J.-H. Kim, S.-J. Kim, E.-C. Song, et al. Circulating Endothelial Progenitor Cells as a New Marker of Endothelial Dysfunction or Repair in Acute Stroke * Supplemental Methods Stroke, May 1, 2008; 39(5): 1441 - 1447. [Abstract] [Full Text] [PDF]

				S. -T. Lee, K. Chu, K. -H. Jung, D. -H. Kim, E. -H. Kim, V. N. Choe, J. -H. Kim, W. -S. Im, L. Kang, J. -E. Park, et al. Decreased number and function of endothelial progenitor cells in patients with migraine Neurology, April 22, 2008; 70(17): 1510 - 1517. [Abstract] [Full Text] [PDF]

				E. M. F. Van Craenenbroeck, C. J. Vrints, S. E. Haine, K. Vermeulen, I. Goovaerts, V. F. I. Van Tendeloo, V. Y. Hoymans, and V. M. A. Conraads A maximal exercise bout increases the number of circulating CD34+/KDR+ endothelial progenitor cells in healthy subjects. Relation with lipid profile J Appl Physiol, April 1, 2008; 104(4): 1006 - 1013. [Abstract] [Full Text] [PDF]

				G. Schlieper, M. Hristov, V. Brandenburg, T. Kruger, R. Westenfeld, A. H. Mahnken, E. Yagmur, G. Boecker, N. Heussen, U. Gladziwa, et al. Predictors of low circulating endothelial progenitor cell numbers in haemodialysis patients Nephrol. Dial. Transplant., March 19, 2008; (2008) gfn103v1. [Abstract] [Full Text] [PDF]

				H. E. Thomas, R. Redgrave, M. S. Cunnington, P. Avery, B. D. Keavney, and H. M. Arthur Circulating Endothelial Progenitor Cells Exhibit Diurnal Variation Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): e21 - e22. [Full Text] [PDF]

				Y. Feng, F. Jacobs, E. Van Craeyveld, C. Brunaud, J. Snoeys, M. Tjwa, S. Van Linthout, and B. De Geest Human ApoA-I Transfer Attenuates Transplant Arteriosclerosis via Enhanced Incorporation of Bone marrow-derived Endothelial Progenitor Cells Arterioscler. Thromb. Vasc. Biol., February 1, 2008; 28(2): 278 - 283. [Abstract] [Full Text] [PDF]

				J. Zoll, V. Fontaine, P. Gourdy, V. Barateau, J. Vilar, A. Leroyer, I. Lopes-Kam, Z. Mallat, J.-F. Arnal, P. Henry, et al. Role of human smooth muscle cell progenitors in atherosclerotic plaque development and composition Cardiovasc Res, February 1, 2008; 77(3): 471 - 480. [Abstract] [Full Text] [PDF]

				T. J. Povsic, K. L. Zavodni, F. L. Kelly, S. Zhu, P. J. Goldschmidt-Clermont, C. Dong, and E. D. Peterson Circulating Progenitor Cells Can Be Reliably Identified on the Basis of Aldehyde Dehydrogenase Activity J. Am. Coll. Cardiol., December 4, 2007; 50(23): 2243 - 2248. [Abstract] [Full Text] [PDF]

				Y. Yodoi, M. Sasahara, T. Kameda, N. Yoshimura, and A. Otani Circulating Hematopoietic Stem Cells in Patients with Neovascular Age-Related Macular Degeneration Invest. Ophthalmol. Vis. Sci., December 1, 2007; 48(12): 5464 - 5472. [Abstract] [Full Text] [PDF]

				M. Gossl, L. O. Lerman, and A. Lerman Frontiers in Nephrology: Early Atherosclerosis A View Beyond the Lumen J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2836 - 2842. [Abstract] [Full Text] [PDF]

				C. Werner, C. H. Kamani, C. Gensch, M. Bohm, and U. Laufs The Peroxisome Proliferator Activated Receptor-{gamma} Agonist Pioglitazone Increases Number and Function of Endothelial Progenitor Cells in Patients With Coronary Artery Disease and Normal Glucose Tolerance Diabetes, October 1, 2007; 56(10): 2609 - 2615. [Abstract] [Full Text] [PDF]

				P.-H. Huang, Y.-H. Chen, Y.-L. Chen, T.-C. Wu, J.-W. Chen, and S.-J. Lin Vascular endothelial function and circulating endothelial progenitor cells in patients with cardiac syndrome X Heart, September 1, 2007; 93(9): 1064 - 1070. [Abstract] [Full Text] [PDF]

				Y. Wang, Y. Zheng, W. Zhang, H. Yu, K. Lou, Y. Zhang, Q. Qin, B. Zhao, Y. Yang, and R. Hui Polymorphisms of KDR Gene Are Associated With Coronary Heart Disease J. Am. Coll. Cardiol., August 21, 2007; 50(8): 760 - 767. [Abstract] [Full Text] [PDF]

				P. E Westerweel, R. K M A C Luijten, I. E Hoefer, H. A Koomans, R. H W M Derksen, and M. C Verhaar Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus Ann Rheum Dis, July 1, 2007; 66(7): 865 - 870. [Abstract] [Full Text] [PDF]

				C. K. Kissel, R. Lehmann, B. Assmus, A. Aicher, J. Honold, U. Fischer-Rasokat, C. Heeschen, I. Spyridopoulos, S. Dimmeler, and A. M. Zeiher Selective Functional Exhaustion of Hematopoietic Progenitor Cells in the Bone Marrow of Patients With Postinfarction Heart Failure J. Am. Coll. Cardiol., June 19, 2007; 49(24): 2341 - 2349. [Abstract] [Full Text] [PDF]

				K.-H. Chang, T. Chan-Ling, E. L. McFarland, A. Afzal, H. Pan, L. C. Baxter, L. C. Shaw, S. Caballero, N. Sengupta, S. L. Calzi, et al. IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development PNAS, June 19, 2007; 104(25): 10595 - 10600. [Abstract] [Full Text] [PDF]